Status
Acquired by GlaxoSmithKline on May 29, 2013
Funding Received
$20.5 Million in 1 Round from 2 Investors
Headquarters:
Basel
Description:
Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.
Categories:
Biotechnology
Website:
http://www.okairos.com

Company Details

Update

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy.

The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Past Team (1)

Update

Funding Rounds (1) - $20.5M

Update

Board Members and Advisors (1)

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • HQ

    Elisabethenstrasse 3

    Basel, CH 4051

    CHE

Images (1)

Update
  • B93e18b839ba3fe0ef50b4d2dec96fe8